




The Mark Foundation at the 2021 AACR Virtual Meeting
Week 1: April 10-15



On-Demand

SESSION NAME AND NUMBER	PRESENTATION TITLE	MFCR INVESTIGATOR
ADT03.OD: Diagnostic Tests for Immunotherapy: Current CLIA Lab Testing and Future Directions	Multiplex immunofluorescence assay development	Janis Taube
ADT08.OD: Advances in Drug Delivery	Vaccine-boosting CAR T cells through the chimeric antigen receptor	Darrell Irvine
AOS10.OD: Diffuse Large B-Cell Lymphoma	Targetable genetic signatures in large B-cell lymphomas	Margaret Shipp
SY07.OD: The Clinical Proteomic Tumor Analysis Consortium: Building a Proteogenomic Atlas of Cancer	Proteomic analysis to inform the biology of drug response in acute myeloid leukemia	Jeffrey Tyner
SY16.OD: Functional Precision Medicine in Cancer	Using patient-derived models for functional precision oncology in advanced breast cancer	Alana Welm
SY21.OD: Drugging KRAS	Multimodal direct targeting of K-Ras (G12C)	Kevan Shokat

On-Demand (Cont'd)

SESSION NAME AND NUMBER	PRESENTATION TITLE	MFCR INVESTIGATOR
SY25.OD: New Approaches to Chimeric Antigen Receptor Engineering	Overcoming immunosuppression with next-generation CAR-T cells	Yvonne Chen
SY27.OD: Germline Influence on Immunotherapy Outcomes	MHC genotype influences response to immune checkpoint blockade	Hannah Carter
SY36.OD: Diet, Clock, and Cancer	Chairperson	Lewis Cantley
SY38.OD: Modeling Metastatic Progression in the Mouse	Activating a collaborative innate-adaptive immune response to restrain breast and ovarian cancer metastasis in mice	Mikala Egeblad
PO.EP01.09: Genome-Wide Association Studies (GWAS) / Post-GWAS	Common genetic variants influence the composition of the tumor immune microenvironment and host anti-tumor responses	Meghana Pagadala
PO.IM02.01: Adoptive Cell Therapy	Reprogramming cancer into antigen presenting cells as a novel immunotherapy	Miles Linde

On-Demand (Cont'd)

SESSION NAME AND NUMBER	PRESENTATION TITLE	MFCR INVESTIGATOR
PO.IM02.05: Immune Monitoring / Clinical Correlates	Longitudinal dynamics of circulating tumor DNA and plasma proteomics predict clinical outcomes to immunotherapy in non-small cell lung cancer	Joseph Murray
PO.MCB04.04: Oncogenic Transcription Factors	Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity	Hadley Sheppard
PO.MCB08.01: Metabolic Pathways	Obesity is associated with lower tumor oxidative phosphorylation (OXPhos) in metastatic melanoma (MM)	Andrew Hahn
PO.MCB09.02: Genomic Profiling of Tumors	Molecular subtypes of head and neck cancer in patients with African ancestry	Nadia Mezghani

On-Demand (Cont'd)

SESSION NAME AND NUMBER	PRESENTATION TITLE	MFCR INVESTIGATOR
PO.MCB09.02: Genomic Profiling of Tumors	An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance	Monica Arniella
PO.TB06.04: Immune Cells in the Tumor Microenvironment	Utilizing endometrial tumor organoids to model cancer immunomodulation	Aaron Nizam
PO.TB10.01: Tumor Evolution and Heterogeneity	TRIPODD: a novel fluorescence imaging platform for in situ quantification of drug distribution and therapeutic response	Nathan McMahon

Live Presentations and Panels

DATE AND TIME	SESSION NAME AND NUMBER	PRESENTATION TITLE	MFCR INVESTIGATOR
4/10: 1:30-3:30 PM EDT	MS.CL01.01: Biomarkers	Early dynamics in peripheral blood immune cell subsets and ctDNA are predictive of outcome to immunotherapy	Michael Hwang
4/10: 1:30-3:30 PM EDT	MS.LBA01: Late-Breaking Minisymposium 1	High quality neoantigens are immunoedited in long term survivors of pancreatic cancer	Marta Luksza
4/10: 1:30-3:30 PM EDT	MS.MCB09.01: Multiomics and Single Cell Deconvolution of Cancer: From Discovery to Patient Stratification and Treatment	Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities	Luciano Garafano
4/10: 4:00-5:45 PM EDT	DDT01: New Drugs on the Horizon: Part 2	Chairperson	Philip Jones

Live Presentations and Panels (Cont'd)

DATE AND TIME	SESSION NAME AND NUMBER	PRESENTATION TITLE	MFCR INVESTIGATOR
4/10: 4:00-6:00 PM EDT	MS.MCB01.01: Cell Growth Signaling Pathways	Characterization of oncogenic KRAS A59 alleles and their cooperation with the MAPK signaling pathway	Christian Johnson
4/11: 10:15 AM-12:45 PM EDT	PL01: Opening Plenary Session: Discovery Science Driving Clinical Breakthroughs	Ancestry and cancer disparities: Genomic sequencing in diverse populations	Melissa Davis
4/11: 2:00-4:00 PM EDT	MS.CH01.01: Cancer Proteomics and Screening Technologies	Patterns and regulation of post translational modifications in cancer	Yifat Geffen
4/11: 2:00-4:00 PM EDT	MS.IM01.01: Mapping the Cellular and Molecular Cues That Control Therapeutic Antitumor Immunity	Obesity-induced impairment of antitumor immunity is associated with an immunosuppressive tumor immune landscape	Barbara Pazdrak
4/11: 4:30-6:00 PM EDT	FO06: The Myths and Realities of the Abscopal Effects	Deciphering the opposing roles of immune pathways influencing the immunogenic effect of radiation	Andy Minn

Live Presentations and Panels (Cont'd)

DATE AND TIME	SESSION NAME AND NUMBER	PRESENTATION TITLE	MFCR INVESTIGATOR
4/12: 4:00-5:30 PM EDT	FO01: Data Science and Machine Learning: Will They Revolutionize Cancer Cure and Research?	Toward clinically integrated computational oncology for precision cancer medicine	Eliezer Van Allen
4/13: 4:30-6:00 PM EDT	FO04: Embracing Entrepreneurship in Cancer Research	Panelist	Angela Koehler
4/14: 2:30-3:00 PM EDT	ADT08.DISC: Panel - Advances in Drug Delivery	Panelist	Darrell Irvine
4/14: 2:30-3:00 PM EDT	SY25.DISC: Panel - New Approaches to Chimeric Antigen Receptor Engineering	Panelist	Yvonne Chen
4/14: 3:30-4:00 PM EDT	SY27.DISC: Panel - Germline Influence on Immunotherapy Outcomes	Panelist	Hannah Carter

Live Presentations and Panels (Cont'd)

DATE AND TIME	SESSION NAME AND NUMBER	PRESENTATION TITLE	MFCR INVESTIGATOR
4/14: 4:30-6:00 PM EDT	FO09: Cancer Cell Dormancy: The Current Paradigm and the Challenges Ahead to Develop New Therapies	Disseminated cancer cell dormancy: A homeostatic seed and soil partnership	Julio Aguirre-Ghiso
4/15: 10:00-10:30 AM EDT	SY38.DISC: Panel-- Modeling Metastatic Progression in the Mouse	Panelist	Mikala Egeblad



[THEMARKFOUNDATION.ORG](https://www.themarkfoundation.org)

1350 AVENUE OF THE AMERICAS, SUITE 2902

NEW YORK, NY 10019

TEL: 646.866.5950

